Between 30 -50% of patients with major depressive disorder (MDD) do not respond to their first antidepressant trial. Genetic variants contribute to the variance in antidepressant response rates. The clinical utility of pharmacogenetics-based decision-support tools (DSTs) is uncertain and has been the topic of much debate.
Introduction
Between 30 -50% of patients with major depressive disorder (MDD) do not respond to their first antidepressant trial. Genetic variants contribute to the variance in antidepressant response rates. The clinical utility of pharmacogenetics-based decision-support tools (DSTs) is uncertain and has been the topic of much debate.
Objectives
To conducted a systematic review and meta-analysis of prospective, randomized controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools (DSTs) relevant to depressive symptom remission in major depressive disorder (MDD).
Methods
Random-effects meta-analysis was performed on RCTs that examined the effect of DSTs on remission rates in MDD. RCT quality was assessed using the Cochrane Collaboration Criteria.
Findings
A total of 1737 eligible subjects from five RCTs were examined. Individuals receiving pharmacogenetic-guided DST therapy (n = 887) were 1.71 (95% CI = 1.17 -2.48, p = 0.005) times more likely to achieve symptom remission relative to individuals who received treatment as usual (n = 850).
Conclusions
Meta-analysis results showed pharmacogenetic-guided prescribing has a positive effect on the likelihood of achieving symptom remission in MDD. Pharmacogenetic-guided prescribing of antidepressants is superior to prescribing as usual in relation to remission likelihood, specifically among those with inadequate response or intolerability to previous psychotropic medications.
